Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
Provided By PR Newswire
Last update: May 15, 2025
-- Presented preclinical data for potentially differentiated HER3 ADC, EO-1022, at AACR Annual Meeting --
-- Expects to file IND application for EO-1022 in 2026 --
Read more at prnewswire.com
